Displaying 1–25 of 10631 results for
Gilead is paying insitro $15 million upfront with additional near-term payments up to $35 million based on operational milestones.
Joe Biden addressed a sold-out audience at University of Pennsylvania, joining a panel conversation about the opioid crisis.
Bristol-Myers Squibb shareholders approved the company’s $74 billion acquisition of rival Celgene, despite activist campaigns to break up the deal.
The US FDA announced that women taking Sprout Pharma's female libido pill, Addyi, do not need to completely avoid alcohol.
Despite negative public opinions and heavy demands, survey respondents indicate rising satisfaction and pride in their work
The FDA has greenlighted Amgen’s new osteoporosis drug for postmenopausal women
Federal prosecutors with the Department of Justice have indicted Indivior for what they call a multibillion-dollar scheme to ratchet up sales of an opioid addiction treatment.
The U.S. Food and Drug Administration, after a preliminary review, cited a lack of certain non-clinical studies to assess the chronic administration of fenfluramine and due to an incorrect dataset.
ViiV is GSK’s HIV drugs division where Pfizer and Shionogi & Co have stakes as well.
Acidic liquids could cause damage to equipment over time through corrosion, which will result in costly breakdowns and downtime without sufficient preventive measures.
Celgene and Acceleron Pharma announced that Celgene has submitted a Biologics License Application (BLA) for one of the drugmaker's most promising experimental blood disease drugs.
Nearly a year and a half after the death of Apotex’s founder and CEO and his wife, the company is reportedly mulling a sale.
Regeneron Pharmaceuticals is investing $800 million into a deal with Alnylam Pharmaceuticals to make treatments using an innovative gene-silencing approach.
United Therapeutics has halted a late stage trial for its pulmonary arterial hypertension candidate after the drug failed to achieve the study's primary endpoint.
Merrimack Pharmaceuticals, an oncology company focused on biomarker-defined cancers, announced that it is abandoning its experimental drug, MM-310, after an early-stage trial involving patients with solid tumors showed that treatment with the drug was cumulatively toxic to patient
Amgen’s multibillion-dollar collaboration with Novartis to jointly develop and market Amgen’s migraine-prevention treatment has resulted in both companies filing lawsuits.
AstraZeneca has entered into an agreement with Japanese-based Daiichi Sankyo to develop and commercialize trastuzumab deruxtecan, a proprietary antibody-drug conjugate (ADC) and potential new targeted medicine for cancer treatment.
Follow these five steps to quench your thirst for insights from your data.
The facilities in Kalundborg, Denmark, will be rebuilt to allow for production beyond diabetes treatments.
Roche, which is looking to expand in gene therapy, will extend its original deadline a month until May 2.
The company plans to rehire all the former AstraZeneca employees to work in the 700,000-square-foot, six-building campus.
The Sackler family are arguing that the lawsuit from the Massachusetts attorney general is misleading.
Combining human reasoning with the machine learning functionality found in advanced analytics applications improves pharma processes
New Jersey-based Heritage Pharmaceuticals is seeking damages from a Port of Virginia blunder that sent a container of its drugs toppling into the Elizabeth River.